Clinical Trial: Trastuzumab Deruxtecan in Advanced Breast Cancer

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180264) titled 'Trastuzumab Deruxtecan in Advanced Breast Cancer' on Sept. 11.

Brief Summary: To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

Study Start Date: Sept., 2025

Study Type: OBSERVATIONAL

Condition: Advanced Breast Cancer

Intervention: DRUG: Trastuzumab deruxtecan

Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Wenjin Yin

Information provided by (Responsible Party): Wenjin Yin, RenJi Hospital

Published by HT Digital Content ...